Compare Msci Inc (MSCI) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Msci Inc vs TransMedics Group Inc — how do they compare? Msci Inc trades at $562 (market cap $40.84B), while TransMedics Group Inc trades at $87.08 (market cap $3.10B). The key difference: Msci Inc is far larger — about 13.2× TransMedics Group Inc's market cap, and Msci Inc pays a 1.46% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| MSCI | TMDX | |
|---|---|---|
Market Cap | $40.84B | $3.10B |
Sector | Financials | Technology |
52-Week High | $643.83 | $150.42 |
52-Week Low | $511.84 | $61.99 |
Enterprise Value | $47.00B | $3.49B |
Dividend Yield | 1.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSCI trades at $563.01, down slightly (-0.01%) with a bearish technical signal. The company maintains strong fundamentals with $3.13B revenue, 40.73% net margin, and consistent earnings beats in three of the last four quarters. Recent acquisitions and strategic partnerships enhance its private markets platform. Analyst consensus remains strongly bullish with a $728.14 price target, representing 29% upside potential from current levels.
The outlook remains positive given MSCI's recurring revenue model, high client retention, and secular growth in private markets. Key risks include execution of recent acquisitions and market sensitivity to index performance. With strong profitability and Wall Street support, the stock presents a compelling long-term opportunity despite near-term technical weakness.
TransMedics Group (TMDX) trades at $87.42, down 1.12% on the day, with a bullish technical outlook from moving averages but bearish oscillators signaling potential overbought conditions. The company reported mixed Q2 2026 results, missing earnings estimates with EPS of $0.44 versus $0.50 expected, while revenue growth remains robust. Recent news highlights an ongoing investigation into fiduciary duties by directors, adding uncertainty.
The stock presents a cautious opportunity with strong analyst support (69% buy ratings) and a consensus price target of $99.57, implying upside, but risks include earnings volatility, margin pressures, and legal scrutiny. Fundamentals show solid profitability with a 22.69% net margin, though valuation multiples like P/E of 23.15 suggest premium pricing relative to historical norms.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
